AndreaBozzo/ceres-open-data-index huggingface dataset:
Compound 526482: [4-[3-[2,2,3,3,4,4,4-Heptafluorobutanoyl(propan-2-yl)amino]-2-trimethylsilyloxypropoxy]-2,3,6-trimethylphenyl] acetate

Chemical compound data from PubChem database. IUPAC Name: [4-[3-[2,2,3,3,4,4,4-heptafluorobutanoyl(propan-2-yl)amino]-2-trimethylsilyloxypropoxy]-2,3,6-trimethylphenyl] acetate. Molecular Formula: C24H34F7NO5Si. Molecular Weight: 577.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
CMS Program Statistics - Medicare Advantage - Outpatient Facility

The CMS Program Statistics – Medicare Advantage, Outpatient Facility tables provide utilization data for outpatient facilities, by Medicare Advantage beneficiaries.

For additional information on enrollment, providers, and Medicare use and payment, visit the CMS Program Statistics page.


Below is the list of tables:


	MDCR OUTPATIENT MA 1.  Medicare Outpatient Facilities: Utilization for Medicare Advantage Beneficiaries, by Type of Entitlement, Yearly Trend
	MDCR OUTPATIENT MA 2.  Medicare Outpatient Facilities: Utilization for Medicare Advantage Beneficiaries, by Demographic Characteristics and Medicare-Medicaid Enrollment Status
	MDCR OUTPATIENT MA 3.  Medicare Outpatient Facilities: Utilization for Medicare Advantage Beneficiaries, by Area of Residence
Patent AT-E399570-T1: [Translated] STABILIZATION OF POLYOXYALKYLENE

The present invention provides a method for producing a medical device, preferably an ophthalmic device, more preferably a contact lens, made of a stabilized poly(oxyalkylene)-containing polymeric material. The method of the invention comprises the steps of: curing, in a mold, a composition comprising (a) a prepolymer having at least one poly(oxyalkylene) unit, (b) a biocompatible organic multi-acid or biocompatible salt thereof in an amount sufficient to improve the stability of the poly(oxyalkylene)-containing polymer made from the composition, (c) optionally a photoinitiator or a thermal initiator, and (d) optionally one or more vinylic monomers, to form the medical device being less susceptible to oxidative degradation; and removing the medical device from the mold.
Title IV-E Reviews — Peer Reviewer Information and Recruitment

The Children's Bureau conducts Title IV-E Foster Care Eligibility Reviews (IV-E Reviews) of Title IV-E agencies to help monitor the agency's compliance in meeting federally mandated requirements, to validate the accuracy of the agency's claims for reimbursement of Title IV-E payments made on behalf of children in foster care, and to identify improper payments. Qualified Peer Reviewers serve on review teams comprised primarily of federal and Title IV-E agency staff during each IV-E Review. For further information on the IV-E Reviews, refer to the Title IV-E Foster Care Eligibility Reviews Fact Sheet.

The IV-E Reviews are on-site reviews that last up to 5 days. Peer Reviewers participate in document reviews of foster care case records and related files; daily and/or final debriefings; and entrance and exit conferences. Peer Reviewers receive reimbursement for participating in training (up to 3 hours), review planning calls, time spent on site (up to 5 days), and travel and per diem costs associated with the IV-E Reviews. Peer reviewers must complete the prerequisite training for selection as a Peer Reviewer.

If you are interested in serving as a Peer Reviewer to supplement the Children's Bureau federal review team for the IV-E Reviews, please review the qualifications, requirements and responsibilities at the links below:

If you are qualified to apply, inquiries regarding a Peer Reviewer Application Package should be directed to:

Child Welfare Compliance Reviews TeamAttn: IV-E ReviewsJBS International, Inc.5515 Security Lane, Suite 800North Bethesda, MD  20852-5007301-565-3260Email: cw@jbsinternational.com, Subject: Peer Reviewer Application

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E40136-T1: [Translated] WATER-SOLUBLE ZINC AND ALUMINUM PTHHALOCYANINES AND THEIR USE AS PHOTOACTIVATORS.

The invention relates to novel zinc and aluminium phthalocyanine compounds of the formula   <IMAGE>   wherein MePc is the zinc or aluminium phthalocyanine ring system, M is hydrogen or a salt-forming cation, P1 is hydrogen or a group of the formula -NH-CN or NH-SO2R3 or the salts thereof, wherein R3 is alkyl, aryl or a heterocyclic ring system, R2 is a neutral, non-solubilizing substituent, n is 1 to 4 and each of m and q is 0 to 3 and p is 0 to 4. These compounds are prepared by starting from the corresponding sulfohalides. The novel compounds are used as photoactivators, especially for bleaching and removing stains from textiles and for combating microorganisms in or on organic or inorganic substrates. The invention also relates to bleaching, detergent and soaking and microbicidal compositions which contain the novel phthalocyanine compounds.
Compound 529089: 11H-Pyrido[2,1-b]quinazolin-11-one, 6,7,8,9-tetrahydro, 9-methyl

Chemical compound data from PubChem database. IUPAC Name: 9-methyl-6,7,8,9-tetrahydropyrido[2,1-b]quinazolin-11-one. Molecular Formula: C13H14N2O. Molecular Weight: 214.26. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Availability of Payment Assistance for Mental Health Services in U.S. Mental Health Treatment Facilities

A substantial proportion of adults and adolescents experience mild to severe mental health symptoms in the past year, but a large proportion of those individuals do not receive treatment.  One of the main reasons they say they do not receive treatment is because the services are too expensive.  This short report uses data from the 2010 National Mental Health Services Survey (N-MHSS) to examine the numbers of mental health treatment facilities that offer payment assistance.  The report finds that most mental health treatment facilities offered some form of payment assistance, either by using a sliding-fee scale or by offering services at no charge to those who cannot afford to pay. These findings are discussed in light of health care reform that may increase the affordability of mental health treatment services.
Patent AT-E401255-T1: [Translated] CHILD-PROOF SAFETY LATCH ON OR FOR CONTAINERS

A container and cap assembly contains a sliding part (82) in the cap (84). The sliding part (82) may be supplied separate from the container and cap assembly, allowing the user to determine if a child-resistant or non-child resistant cap is formed. In the child resistant embodiment, the sliding part (82) is configured within the cap (84) whereby at least a portion of the sliding part protrudes out from the cap in a location near or proximate to a hinge (40). To open the cap, the user applies sufficient force to the sliding part (82), pushing it in a direction away from the hinge (40) so that at least a portion the sliding part protrudes out of the portion of the cap that is substantially opposite the hinge. Then the user applies a second sufficient force in an upward direction to open the cap (84).
Compound 530201: 1H-Indole-3-propanoic acid, 1-(trimethylsilyl)-, trimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 3-(1-trimethylsilylindol-3-yl)propanoate. Molecular Formula: C17H27NO2Si2. Molecular Weight: 333.6. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 525464: Propane, 2,2-bis(ethylthio)-

Chemical compound data from PubChem database. IUPAC Name: 2,2-bis(ethylsulfanyl)propane. Molecular Formula: C7H16S2. Molecular Weight: 164.3. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Patent AT-E399772-T1: [Translated] METHOD FOR PRODUCING PROPYLENE OXIDE

A process for producing propylene oxide, which comprises steps described below, wherein isopropylbenzene hydroperoxide supplied to an epoxidation step has not undergone a heat history including heating at a temperature not lower than the temperature (t  DEG C) represented by the following equation(1), <DF NUM="(1)">t ( DEG C) = 150 -0.8 x W </DF> W: content (% by weight) of isopropylbenzene hydroperoxide in a solution containing isopropylbenzene hydroperoxide:   oxidation step; a step in which isopropylbenzene is oxidized to obtain isopropylbenzene hydroperoxide, epoxidation step; a step in which isopropylbenzene hydroperoxide obtained in the oxidation step is reacted with propylene to obtain propylene oxide and cumyl alcohol, and hydrogenolysis step; a step in which cumyl alcohol obtained in the epoxidation step is subjected to hydrogenolysis to obtain isopropylbenzene, and said isopropylbenzene is recycled to the oxidation step as a raw material for the oxidation step.
Child and Family Services Reviews Update

The Child and Family Services Reviews Update is a newsletter distributed periodically by e-mail and designed for professionals interested in the Federal Child and Family Services Reviews. It is supported by the Children's Bureau, Administration for Children and Families, U.S. Department of Health and Human Services and published by the Child Welfare Reviews Project.

For more information about the Update or to subscribe, contact the Child Welfare Reviews Project. Links to previously distributed issues of the Child and Family Services Reviews Update are provided below:

Metadata-only record linking to the original dataset. Open original dataset below.
Patent AT-E399687-T1: [Translated] RAIN DETECTION APPARATUS AND METHOD

A rain detection apparatus and method, comprising a camera (10) adapted to view a surface (16) and a processor (12) adapted to capture at least one image from the camera (10), in which the processor (12) is further adapted to generate at least one signal indicative of the presence of rain on the surface from information contained in the at least one captured image and to, optionally drive surface cleaning apparatus in response thereto, in which the apparatus is adapted to capture images focussed at a plurality of distances; in which the processor includes edge detection means adapted to detect edges visible in the at least one captured image and difference means adapted to calculate the difference between the number of edges visible between differing images; and in which the edge detection means is further adapted to disregard edges close to areas of light larger than the largest raindrop that is desired or expected to be detected.
Compound 527368: 18,22-Dimethyl-triacontyl cyanide

Chemical compound data from PubChem database. IUPAC Name: 19,23-dimethylhentriacontanenitrile. Molecular Formula: C33H65N. Molecular Weight: 475.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Compound 530182: Histidine, N,1-bis-(trimethylsilyl)-, trimethylsilyl ester

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-(trimethylsilylamino)-3-(1-trimethylsilylimidazol-4-yl)propanoate. Molecular Formula: C15H33N3O2Si3. Molecular Weight: 371.7. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Drug Abuse Warning Network (DAWN): National Estimates of Polysubstance Involved Emergency Department Visits

This report presents data from DAWN to describe national estimates of polysubstance-involved emergency department (ED) visits in the United States in 2024. It provides estimates of polysubstance-involved ED visits by (1) patient characteristics, (2) psychoactive drug involved, and (3) co-occurrence (or combination) of psychoactive drugs.
Physiology in medicine: importance of hypoxic pulmonary vasoconstriction in maintaining arterial oxygenation during acute respiratory failure

Hypoxic pulmonary vasoconstriction continues to attract interest more than half a century after its original report because of persistent mystery about its biochemical mechanism and its exact physiological function. Recent work suggests an important role for pulmonary arteriolar smooth muscle cell oxygen-sensitive voltage-dependent potassium channels. Inhibition of these channels by decreased PO2 inhibits outward potassium current, causing membrane depolarization, and calcium entry through voltage-dependent calcium channels. Endothelium-derived vasoconstricting and vasodilating mediators modulate this intrinsic smooth muscle cell reactivity to hypoxia. However, refined modeling of hypoxic pulmonary vasoconstriction operating as a feedback mechanism in inhomogeneous lungs, using more realistic stimulus-response curves and confronted with direct measurements of regional blood flow distribution, shows a more effective than previously assessed ability of this remarkable intrapulmonary reflex to improve gas exchange and arterial oxygenation. Further studies could show clinical benefit of pharmacological manipulation of hypoxic pulmonary vasoconstriction, in circumstances of life-threatening hypoxemia.
Compound 530160: Trimethylsilyl 2-(trimethylsilylamino)-5-[[(trimethylsilylamino)-trimethylsilyloxymethylidene]amino]pentanoate

Chemical compound data from PubChem database. IUPAC Name: trimethylsilyl 2-(trimethylsilylamino)-5-[[(trimethylsilylamino)-trimethylsilyloxymethylidene]amino]pentanoate. Molecular Formula: C18H45N3O3Si4. Molecular Weight: 463.9. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Selected highlights from the 50

The recent scientific session of the American College of Cardiology (ACC), held in Orlando, provided a forum for ongoing cardiovascular clinical trials from around the world. The high point was clearly the first ever release of results from the CURE study. The Late-Breaking Clinical Trials sessions also featured results and interim data from other trials such as MIRACLE, CAPRICORN, SVG WRIST, RITZ 2, SoS and PRINCE. New applications for data from the OPUS-TIMI16 trial were discussed and promising results from initial studies into the experimental drug ALT-711 showed the way for further studies.
Provisional Deaths Due to Respiratory Illnesses

The Chicago Department of Public Health (CDPH) receives weekly deidentified provisional death certificate data for all deaths that occur in Chicago, which can include both Chicago and non-Chicago residents from the Illinois Department of Public Health (IDPH) Illinois Vital Records System (IVRS). CDPH scans for keywords to identify deaths with COVID-19, influenza, or respiratory syncytial virus (RSV) listed as an immediate cause of death, contributing factor, or other significant condition. The percentage of all reported deaths that are attributed to COVID-19, influenza, or RSV is calculated as the number of deaths for each respective disease divided by the number of deaths from all causes, multiplied by 100.  

This dataset reflects death certificates that have been submitted to IVRS at the time of transmission to CDPH each week – data from previous weeks are not updated with any new submissions to IVRS. As such, estimates in this dataset may differ from those reported through other sources. This dataset can be used to understand trends in COVID-19, influenza, and RSV mortality in Chicago but does not reflect official death statistics.  

Source: Provisional deaths from the Illinois Department of Public Health Illinois Vital Records System.
Compound 530334: Tridecane, 6-butyl-7-propyl

Chemical compound data from PubChem database. IUPAC Name: 6-butyl-7-propyltridecane. Molecular Formula: C20H42. Molecular Weight: 282.5. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.
Respiratory Research: a new multidisciplinary journal for a new age (http://respiratory-research.com)

I am delighted to welcome you to the first printed issue ofRespiratory Research. This new journal, available both on the World Wide Web and in print, will provide timely reviews and rapid publication of primary research in respiratory medicine. The online version ofRespiratory Researchwill be the primary place of publication, where articles appear in full, as soon as they are ready for publication. In fact, the journal website (http://respiratory-research.com) has been open since June 2000, and many of the articles appearing in this issue have been available online for many weeks. The online environment not only allows information to be widely disseminated, but also provides a forum for discussion and the possibility of rapid feedback. Many helpful comments have already been sent to us, and will be incorporated as the journal develops.
NNDSS - TABLE 1Y. Mumps to Novel influenza A virus infections

NNDSS - TABLE 1Y. Mumps to Novel influenza A virus infections - 2022. In this Table, provisional cases* of notifiable diseases are displayed for United States, U.S. territories, and Non-U.S. residents.

Notes:

•	These are weekly cases of selected infectious national notifiable diseases, from the National Notifiable Diseases Surveillance System (NNDSS). NNDSS data reported by the 50 states, New York City, the District of Columbia, and the U.S. territories are collated and published weekly as numbered tables available at https://www.cdc.gov/nndss/data-statistics/index.html. Cases reported by state health departments to CDC for weekly publication are subject to ongoing revision of information and delayed reporting. Therefore, numbers listed in later weeks may reflect changes made to these counts as additional information becomes available. Case counts in the tables are presented as published each week. See also Guide to Interpreting Provisional and Finalized NNDSS Data at https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
• Notices, errata, and other notes are available in the Notice To Data Users page at https://wonder.cdc.gov/nndss/NTR.html.
•	The list of national notifiable infectious diseases and conditions and their national surveillance case definitions are available at https://ndc.services.cdc.gov/. This list incorporates the Council of State and Territorial Epidemiologists (CSTE) position statements approved by CSTE for national surveillance.

Footnotes:

*Case counts for reporting years 2021 and 2022 are provisional and subject to change. Cases are assigned to the reporting jurisdiction submitting the case to NNDSS, if the case's country of usual residence is the U.S., a U.S. territory, unknown, or null (i.e. country not reported); otherwise, the case is assigned to the 'Non-U.S. Residents' category. Country of usual residence is currently not reported by all jurisdictions or for all conditions. For further information on interpretation of these data, see https://www.cdc.gov/nndss/docs/Readers-Guide-WONDER-Tables-20210421-508.pdf.
†Previous 52 week maximum and cumulative YTD are determined from periods of time when the condition was reportable in the jurisdiction (i.e., may be less than 52 weeks of data or incomplete YTD data).
U: Unavailable — The reporting jurisdiction was unable to send the data to CDC or CDC was unable to process the data.
-: No reported cases — The reporting jurisdiction did not submit any cases to CDC.
N: Not reportable — The disease or condition was not reportable by law, statute, or regulation in the reporting jurisdiction.
NN: Not nationally notifiable — This condition was not designated as being nationally notifiable.
NP: Nationally notifiable but not published.
NC: Not calculated — There is insufficient data available to support the calculation of this statistic.
Cum: Cumulative year-to-date counts.
Max: Maximum — Maximum case count during the previous 52 weeks.
Complicated infective endocarditis necessitating ICU admission: clinical course and prognosis

Aim
          To study incidence, clinical course and prognostic factors in patients admitted to medical intensive care units (ICUs) because of a complicated course of infective endocarditis.
        
        
          Method
          This was a retrospective multicenter observational study of 4106 patients admitted to four medical ICUs in one tertiary hospital and one university hospital between 1994 and 1999.
        
        
          Results
          Infective endocarditis was identified in 33 (0.8%) patients. Of these, 26 were male, mean age was 59 ± 12 and APACHE-III score was 75 ± 31. Reasons for transfer to the ICU were congestive heart failure in 64%, septic shock in 21%, neurological deterioration in 15% and cardiopulmonary resuscitation in 9%. Inotropes or vasoconstrictors were required in 73% and multiorgan failure developed in 64% of the patients. Prosthetic valve endocarditis was present in 21%. Gram-positive cocci were found in 96% of all positive cultures; cultures were negative in 27% of the patients. Transthoracic echocardiograms were diagnostic in only 33% and transesophageal studies were required in 91% to confirm diagnosis or fully to delineate the extent of disease. Surgical intervention was performed in 60% of the patients, and the remaining 40% were only treated medically. The APACHE-III score on admission did not differ statistically between the two groups (69 ± 30 versus 84 ± 34, P = 0.17). In-patient mortality was 84% in patients treated medically, and 35% in surgically treated patients. Using multivariate analysis, acute renal failure on admission was identified as the independent single predictor for in-patient death (OR 5, 95% CI 1.04–24.03, P = 0.04).
        
        
          Conclusion
          The prognosis for patients with infective endocarditis requiring admission to a medical ICU is serious. Nevertheless, the data suggest that surgical intervention may be successfully performed in a substantial number of patients despite the presence of severe shock and occurrence of multiorgan failure.
Benefits and Cost Sharing PUF - PY2016

The Benefits and Cost Sharing PUF (BenCS-PUF) is one of the seven files that make up the Marketplace PUF. The BenCS-PUF contains plan-level data on essential health benefits, coverage limits, and cost sharing for each QHP and SADP. These data either originate from the Plans &amp; Benefits template (i.e., template field), an Excel-based form used by issuers to describe their plans in the QHP/SADP application process, or were generated by CCIIO for use in data processing (i.e., system-generated).
Nursing Home Cost Report (RHCF): 2020

The Nursing Home Cost Report (RHCF) is a uniform report completed by New York nursing homes to report income, expenses, assets, liabilities, and statistics to the Department of Health (DOH). Under DOH regulations (Part 86-2.2), nursing homes are required to file financial and statistical data with DOH annually. The data filed is part of the cost report and is received electronically through a secured network. This data is used to develop Medicaid rates, assist in the formulation of reimbursement methodologies, and analyze trends.
Compound 528047: Indene, 3a,4,7,7a-tetrahydro-6-methyl

Chemical compound data from PubChem database. IUPAC Name: 6-methyl-3a,4,7,7a-tetrahydro-1H-indene. Molecular Formula: C10H14. Molecular Weight: 134.22. This dataset contains comprehensive chemical information including structural data, physical properties, and biological activities. Useful for drug discovery, chemical research, and educational purposes.